Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 175.15 Thousand AUD | -28.82% |
| 2022 | 246.07 Thousand AUD | 162.02% |
| 2021 | 93.91 Thousand AUD | -43.5% |
| 2020 | 166.23 Thousand AUD | 71.04% |
| 2019 | 97.18 Thousand AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | -100.0% |
| 2001 | 39.19 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| 1997 | - AUD | 0.0% |
| 1996 | - AUD | -100.0% |
| 1995 | 1000.00 AUD | 0.0% |
| 1994 | - AUD | 0.0% |
| 1993 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - AUD | -100.0% |
| 2024 Q2 | 137.41 Thousand AUD | 0.0% |
| 2023 Q3 | 98.22 Thousand AUD | -53.47% |
| 2023 Q4 | 175.15 Thousand AUD | 78.32% |
| 2023 Q1 | 137.41 Thousand AUD | -44.16% |
| 2023 FY | 175.15 Thousand AUD | -28.82% |
| 2023 Q2 | 211.08 Thousand AUD | 53.62% |
| 2022 Q4 | 246.07 Thousand AUD | 40.49% |
| 2022 FY | 246.07 Thousand AUD | 162.02% |
| 2022 Q1 | - AUD | -100.0% |
| 2022 Q2 | 54.08 Thousand AUD | 0.0% |
| 2022 Q3 | 175.15 Thousand AUD | 223.85% |
| 2021 Q3 | 13.7 Thousand AUD | -89.54% |
| 2021 Q4 | 93.91 Thousand AUD | 585.35% |
| 2021 Q2 | 131.01 Thousand AUD | 161.96% |
| 2021 FY | 93.91 Thousand AUD | -43.5% |
| 2021 Q1 | 50.01 Thousand AUD | -69.91% |
| 2020 FY | 166.23 Thousand AUD | 71.04% |
| 2020 Q1 | - AUD | -100.0% |
| 2020 Q2 | 53.15 Thousand AUD | 0.0% |
| 2020 Q3 | 93.2 Thousand AUD | 75.34% |
| 2020 Q4 | 166.23 Thousand AUD | 78.36% |
| 2019 Q2 | 51.6 Thousand AUD | 0.0% |
| 2019 FY | 97.18 Thousand AUD | 0.0% |
| 2019 Q1 | - AUD | 0.0% |
| 2019 Q4 | 97.18 Thousand AUD | 1162.85% |
| 2019 Q3 | 7696.00 AUD | -85.09% |
| 2018 Q2 | - AUD | 0.0% |
| 2018 Q3 | - AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2018 Q1 | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 Q3 | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q3 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q1 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | - AUD | -100.0% |
| 2001 FY | 39.19 Thousand AUD | 0.0% |
| 2001 Q4 | 39.19 Thousand AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 Q4 | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| 1997 FY | - AUD | 0.0% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | - AUD | -100.0% |
| 1995 FY | 1000.00 AUD | 0.0% |
| 1994 FY | - AUD | 0.0% |
| 1993 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | 90.901% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.575% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 56.414% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.362% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 92.47% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.596% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.412% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 81.529% |
| Marizyme, Inc. | 18.71 Million USD | 99.064% |
| Genus plc | 233.1 Million USD | 99.925% |
| Pharming Group N.V. | 171.54 Million USD | 99.898% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 80.277% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 86.964% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 76.647% |
| ContraFect Corporation | 2.88 Million USD | 93.92% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 87.89% |
| IMV Inc. | 28.88 Million USD | 99.394% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 96.905% |
| ONE Bio Corp. | 19.71 Million USD | 99.112% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.695% |
| Mesoblast Limited | 118.7 Million USD | 99.852% |
| MultiCell Technologies, Inc. | 202.58 USD | -86360.164% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.471% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.958% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 72.202% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 85.741% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 95.751% |
| Biomind Labs Inc. | 735.54 Thousand USD | 76.187% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 94.212% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.652% |
| Skye Bioscience, Inc. | 4.61 Million USD | 96.205% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 51.308% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 94.023% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -23.766% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -29.275% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.017% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -581.018% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 88.282% |
| Q BioMed Inc. | 4.1 Million USD | 95.738% |
| GB Sciences, Inc. | 1.75 Million USD | 90.044% |
| Alpha Cognition Inc. | 1.22 Million USD | 85.648% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Agentix Corp. | 50 Thousand USD | -250.302% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.741% |
| Enzolytics Inc. | 996.33 Thousand USD | 82.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | 97.302% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 31.472% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 92.244% |
| argenx SE | 20 Million USD | 99.124% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.616% |
| HST Global, Inc. | 98.31 Thousand USD | -78.146% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 29.579% |
| Halberd Corporation | 150 Thousand USD | -16.767% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.524% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1612.968% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 93.534% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 92.695% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 23.612% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -17.825% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 12.693% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 92.038% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.138% |
| Kadimastem Ltd | 891.22 Thousand USD | 80.347% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 96.282% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 29.991% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -421.19% |
| Cell Source, Inc. | 9.25 Million USD | 98.107% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 76.838% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 76.838% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 63.833% |
| Itoco Inc. | 228.37 Thousand USD | 23.306% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 16.98% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 96.485% |
| International Stem Cell Corporation | 4.17 Million USD | 95.808% |
| CytoDyn Inc. | 30.07 Million USD | 99.418% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 50.22% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.76% |
| SYBLEU INC | 477.5 Thousand USD | 63.319% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -42.98% |
| Rebus Holdings, Inc. | 310 Thousand USD | 43.5% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 96.301% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -180.632% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 91.969% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.894% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.96% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 88.74% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 34.645% |
| Neutra Corp. | 54.15 Thousand USD | -223.419% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 90.429% |
| PureTech Health plc | 25.51 Million USD | 99.313% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 85.693% |
| IXICO plc | 472.02 Thousand USD | 62.894% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.87% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.719% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.811% |